Doi T - Search Results

1

Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung Cancer.

Hong DS, Gopal AK, Shoushtari AN, Patel SP, He AR, Doi T, Ramalingam SS, Patnaik A, Sandhu S, Chen Y, Davis CB, Fisher TS, Huang B, Fly KD, Ribas A. Hong DS, et al. Among authors: doi t. Front Immunol. 2022 Aug 2;13:897991. doi: 10.3389/fimmu.2022.897991. eCollection 2022. Front Immunol. 2022. PMID: 35983060 Free PMC article.

2

Phase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer.

Oh DY, Doi T, Shirao K, Lee KW, Park SR, Chen Y, Yang L, Valota O, Bang YJ. Oh DY, et al. Among authors: doi t. Cancer Res Treat. 2015 Oct;47(4):687-96. doi: 10.4143/crt.2014.225. Epub 2015 Feb 12. Cancer Res Treat. 2015. PMID: 25687867 Free PMC article. Clinical Trial.

3

Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer.

Segal NH, He AR, Doi T, Levy R, Bhatia S, Pishvaian MJ, Cesari R, Chen Y, Davis CB, Huang B, Thall AD, Gopal AK. Segal NH, et al. Among authors: doi t. Clin Cancer Res. 2018 Apr 15;24(8):1816-1823. doi: 10.1158/1078-0432.CCR-17-1922. Epub 2018 Mar 16. Clin Cancer Res. 2018. PMID: 29549159 Clinical Trial.

4

Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody.

Harding JJ, Moreno V, Bang YJ, Hong MH, Patnaik A, Trigo J, Szpurka AM, Yamamoto N, Doi T, Fu S, Calderon B, Velez de Mendizabal N, Calvo E, Yu D, Gandhi L, Liu ZT, Galvao VR, Leow CC, de Miguel MJ. Harding JJ, et al. Among authors: doi t. Clin Cancer Res. 2021 Apr 15;27(8):2168-2178. doi: 10.1158/1078-0432.CCR-20-4405. Epub 2021 Jan 29. Clin Cancer Res. 2021. PMID: 33514524 Clinical Trial.

5

Characteristics and clinical outcomes of patients with advanced gastric or gastroesophageal cancer treated in and out of randomized clinical trials of first-line immune checkpoint inhibitors.

Aoki Y, Kawazoe A, Kubota Y, Chida K, Mishima S, Kotani D, Nakamura Y, Kuboki Y, Bando H, Kojima T, Doi T, Yoshino T, Kuwata T, Shitara K. Aoki Y, et al. Among authors: doi t. Int J Clin Oncol. 2022 Sep;27(9):1413-1420. doi: 10.1007/s10147-022-02200-1. Epub 2022 Jun 17. Int J Clin Oncol. 2022. PMID: 35713753

6

Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan.

Kiyota N, Tahara M, Kadowaki S, Fuse N, Doi T, Minami H, Ohtsu A. Kiyota N, et al. Among authors: doi t. Jpn J Clin Oncol. 2009 Apr;39(4):225-30. doi: 10.1093/jjco/hyp002. Epub 2009 Feb 10. Jpn J Clin Oncol. 2009. PMID: 19211574

7

KRAS mutations detected by the amplification refractory mutation system-Scorpion assays strongly correlate with therapeutic effect of cetuximab.

Bando H, Yoshino T, Tsuchihara K, Ogasawara N, Fuse N, Kojima T, Tahara M, Kojima M, Kaneko K, Doi T, Ochiai A, Esumi H, Ohtsu A. Bando H, et al. Among authors: doi t. Br J Cancer. 2011 Jul 26;105(3):403-6. doi: 10.1038/bjc.2011.247. Epub 2011 Jul 5. Br J Cancer. 2011. PMID: 21730978 Free PMC article.

8

Early clinical outcomes of anal squamous cell carcinoma treated with concurrent chemoradiotherapy with 5-Fluorouracil plus mitomycin C in Japanese patients: experience at a single institution.

Satake H, Yoshino T, Sasaki T, Bando H, Yoda Y, Ikematsu H, Kojima T, Fuse N, Zenda S, Doi T, Kaneko K, Ohtsu A. Satake H, et al. Among authors: doi t. Jpn J Clin Oncol. 2012 Sep;42(9):861-4. doi: 10.1093/jjco/hys093. Epub 2012 Jun 19. Jpn J Clin Oncol. 2012. PMID: 22717459

9

A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors.

Doi T, Shitara K, Kojima T, Yoshino T, Dontabhaktuni A, Rebscher H, Tang S, Cosaert J, Ohtsu A. Doi T, et al. Cancer Chemother Pharmacol. 2016 Jun;77(6):1253-62. doi: 10.1007/s00280-016-3041-7. Epub 2016 Apr 30. Cancer Chemother Pharmacol. 2016. PMID: 27139036 Clinical Trial.

10

Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma.

Hatogai K, Kitano S, Fujii S, Kojima T, Daiko H, Nomura S, Yoshino T, Ohtsu A, Takiguchi Y, Doi T, Ochiai A. Hatogai K, et al. Among authors: doi t. Oncotarget. 2016 Jul 26;7(30):47252-47264. doi: 10.18632/oncotarget.10055. Oncotarget. 2016. PMID: 27322149 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,573 results

Search Page